Skip to main content
Premium Trial:

Request an Annual Quote

Genomics Collaborative, ActivX Biosciences Team to Identify Colon Cancer Protein Targets

NEW YORK, Aug. 8 – Genomics Collaborative and ActivX Biosciences have initiated a joint program to identify proteins with potential as drug targets for colon cancer, Genomics Collaborative said on Wednesday. 

Genomics Collaborative, which has assembled a large collection of human DNA, sera, and tissue samples linked to specific diseases, will supply clinical samples to ActivX for analysis. ActivX, meanwhile, will screen those samples for proteins associated with colon cancer by using its platform for synthesizing chemical probes that bind with active sites specific to whole protein families.

The companies did not disclose financial details or how they would share any intellectual property generated in the collaboration.

“By applying the power of our collective capabilities to extremely well-characterized colon cancer tissue, this partnership will position both companies to uncover promising new targets in this disease," Michael Pellini, CEO of Cambridge, Mass.-based Genomics Collaborative, said in a statement.

In July, San Diego-based ActivX announced the closing of a $20 million private placement that it said would help it hire new scientists to further develop its platform.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.